1	Earn	earn	VBP	pb=earn.01	0	root	_
2	Free	free	NNP	_	3	nn	_
3	CME	cme	NNP	_	4	nn	_
4	Credits	credits	NNP	p2=NNPS	1	dobj	1:A1=PPT
5	by	by	IN	_	1	prep	1:AM-MNR
6	reading	read	VBG	pb=read.01	5	pcomp	_
7	the	the	DT	_	10	det	_
8	latest	late	JJS	_	10	amod	_
9	medical	medical	JJ	_	10	amod	_
10	news	news	NN	_	6	dobj	6:A1=PPT
11	in	in	IN	_	10	prep	_
12	your	your	PRP$	_	13	poss	_
13	specialty	specialty	NN	_	11	pobj	_
14	.	.	.	_	1	punct	_

1	Note	note	VB	p2=VBP|pb=note.01	0	root	_
2	that	that	IN	_	12	complm	_
3	this	this	DT	_	5	det	_
4	randomized	randomized	JJ	p2=VBN	5	amod	_
5	trial	trial	NN	_	12	nsubj	12:A0
6	of	of	IN	_	5	prep	_
7	an	an	DT	_	11	det	_
8	IL	il	NN	p2=NNP	10	hmod	_
9	-	-	HYPH	_	10	hyph	_
10	6	0	CD	_	11	nn	_
11	antibody	antibody	NN	_	6	pobj	_
12	demonstrated	demonstrate	VBD	p2=VBN|pb=demonstrate.01	1	ccomp	1:A1=PPT
13	efficacy	efficacy	NN	p2=JJ	12	dobj	12:A1=PPT
14	in	in	IN	_	12	prep	12:AM-LOC
15	ameliorating	ameliorate	VBG	p2=JJ|pb=ameliorate.01	14	pcomp	_
16	symptoms	symptom	NNS	_	15	dobj	15:A1=PPT
17	in	in	IN	_	15	prep	_
18	children	child	NNS	_	17	pobj	_
19	with	with	IN	_	18	prep	_
20	juvenile	juvenile	JJ	p2=NN	22	amod	_
21	rheumatoid	rheumatoid	JJ	p2=NN	22	amod	_
22	arthritis	arthritis	NN	_	19	pobj	_
23	.	.	.	_	1	punct	_

1	Be	be	VB	pb=be.01	0	root	_
2	aware	aware	JJ	_	1	acomp	1:A2=PRD
3	that	that	IN	_	11	complm	_
4	the	the	DT	_	6	det	_
5	randomized	randomize	VBN	p2=JJ|pb=randomize.01	6	amod	_
6	portion	portion	NN	_	11	nsubj	5:A1=PPT;11:A2=GOL
7	of	of	IN	_	6	prep	_
8	the	the	DT	_	9	det	_
9	trial	trial	NN	_	7	pobj	_
10	only	only	RB	_	11	advmod	11:AM-ADV
11	included	include	VBD	pb=include.01	2	ccomp	_
12	patients	patient	NNS	_	11	dobj	16:A0;11:A1=PPT
13	who	who	WP	_	16	nsubj	16:R-A0
14	had	have	VBD	_	16	aux	_
15	already	already	RB	_	16	advmod	16:AM-TMP
16	demonstrated	demonstrate	VBN	p2=VBD|pb=demonstrate.01	12	rcmod	_
17	a	a	DT	_	18	det	_
18	response	response	NN	_	16	dobj	16:A1=PPT
19	to	to	IN	_	18	prep	_
20	the	the	DT	_	21	det	_
21	agent	agent	NN	_	19	pobj	_
22	.	.	.	_	1	punct	_

1	Treatment	treatment	NN	p2=NNP	7	nsubj	7:A1=PPT
2	with	with	IN	_	1	prep	_
3	tocilizumab	tocilizumab	NN	p2=NNP	2	pobj	_
4	(	(	-LRB-	_	1	punct	_
5	Actemra	actemra	NNP	p2=NN	1	appos	_
6	)	)	-RRB-	_	7	punct	_
7	resulted	result	VBD	pb=result.01	32	ccomp	_
8	in	in	IN	p2=RP	7	prep	7:A2=LOC
9	fewer	few	JJR	_	12	amod	_
10	early	early	JJ	p2=RB	11	amod	_
11	disease	disease	NN	p2=VBP	12	nn	_
12	flares	flare	NNS	_	8	pobj	_
13	and	and	CC	_	12	cc	_
14	significant	significant	JJ	_	16	amod	_
15	symptomatic	symptomatic	JJ	_	16	amod	_
16	improvements	improvement	NNS	_	12	conj	_
17	among	among	IN	_	16	prep	_
18	children	child	NNS	_	17	pobj	_
19	with	with	IN	_	18	prep	_
20	polyarticular	polyarticular	JJ	p2=NNS	23	amod	_
21	juvenile	juvenile	JJ	_	23	amod	_
22	idiopathic	idiopathic	JJ	p2=NN	23	amod	_
23	arthritis	arthritis	NN	_	19	pobj	_
24	(	(	-LRB-	_	25	punct	_
25	JIA	jia	NNP	_	23	appos	_
26	)	)	-RRB-	_	25	punct	_
27	,	,	,	_	32	punct	_
28	a	a	DT	_	31	det	_
29	phase	phase	NN	_	31	nn	_
30	III	iii	NNP	p2=CD	31	nn	_
31	study	study	NN	_	32	nsubj	32:A0=PAG
32	found	find	VBD	pb=find.01	0	root	_
33	.	.	.	_	32	punct	_

1	Among	among	IN	_	10	prep	10:AM-LOC
2	patients	patient	NNS	_	1	pobj	3:A0=PAG
3	receiving	receive	VBG	pb=receive.01	2	partmod	_
4	tocilizumab	tocilizumab	NN	p2=JJ	3	dobj	3:A1=PPT
5	,	,	,	_	4	punct	_
6	25.6	0	CD	_	7	num	_
7	%	%	NN	_	4	conj	_
8	of	of	IN	_	7	prep	_
9	patients	patient	NNS	_	8	pobj	_
10	experienced	experience	VBD	p2=VBN|pb=experience.01	0	root	_
11	a	a	DT	_	12	det	_
12	flare	flare	NN	_	10	dobj	10:A1=PAG
13	by	by	IN	_	10	prep	10:AM-TMP
14	week	week	NN	_	13	pobj	_
15	40	0	CD	_	14	num	_
16	compared	compare	VBN	_	10	prep	10:AM-ADV
17	with	with	IN	_	16	prep	_
18	48.1	0	CD	_	19	num	_
19	%	%	NN	_	17	pobj	_
20	among	among	IN	_	19	prep	_
21	those	those	DT	_	20	pobj	22:A1=PPT
22	randomized	randomize	VBN	p2=JJ|pb=randomize.01	21	partmod	_
23	to	to	IN	p2=TO	22	prep	22:A2=GOL
24	placebo	placebo	NN	_	23	pobj	_
25	,	,	,	_	19	punct	_
26	for	for	IN	_	16	prep	_
27	an	an	DT	_	29	det	_
28	adjusted	adjusted	JJ	p2=VBN	29	amod	_
29	difference	difference	NN	_	26	pobj	_
30	of	of	IN	_	29	prep	_
31	-	-	HYPH	p2=$	32	hyph	_
32	0.21	0	CD	_	30	pobj	_
33	in	in	IN	_	29	prep	_
34	rate	rate	NN	_	33	pobj	_
35	of	of	IN	_	34	prep	_
36	flares	flare	NNS	p2=FW	35	pobj	_
37	(	(	-LRB-	_	40	punct	_
38	95	0	CD	_	39	num	_
39	%	%	NN	_	40	nn	_
40	CI	ci	NNP	p2=NN	36	appos	_
41	minus	minus	CC	p2=NNP	40	cc	_
42	0.35	0	CD	_	44	hmod	_
43	-	-	HYPH	_	44	hyph	_
44	minus	minus	NN	p2=CC	40	conj	_
45	0.08	0	CD	_	44	appos	_
46	,	,	,	_	44	punct	_
47	P=0.0024	p=0.0024	NNP	p2=NN	44	appos	_
48	)	)	-RRB-	_	44	punct	_
49	,	,	,	_	10	punct	_
50	according	accord	VBG	_	16	prep	_
51	to	to	IN	_	50	prep	_
52	Hermine	hermine	NNP	p2=NN	54	nn	_
53	I.	i.	NNP	_	54	nn	_
54	Brunner	brunner	NNP	_	51	pobj	_
55	,	,	,	_	54	punct	_
56	MD	md	NNP	_	54	appos	_
57	,	,	,	_	54	punct	_
58	of	of	IN	_	54	prep	_
59	Cincinnati	cincinnati	NNP	_	60	nn	_
60	Children	children	NNP	p2=NNPS	62	poss	_
61	's	's	POS	_	60	possessive	_
62	Hospital	hospital	NNP	p2=NN	58	pobj	_
63	,	,	,	_	54	punct	_
64	and	and	CC	_	54	cc	_
65	colleagues	colleague	NNS	_	54	conj	_
66	.	.	.	_	10	punct	_

1	In	in	IN	_	7	prep	7:AM-LOC
2	the	the	DT	_	4	det	_
3	placebo	placebo	NN	_	4	nn	_
4	group	group	NN	_	1	pobj	_
5	,	,	,	_	7	punct	_
6	flares	flare	NNS	p2=VBZ	7	nsubj	7:A1=PPT;9:A1=PPT
7	began	begin	VBD	pb=begin.01	16	ccomp	16:A1=PPT
8	to	to	TO	_	9	aux	_
9	appear	appear	VB	pb=appear.01	7	xcomp	7:C-A1
10	after	after	IN	_	9	prep	9:AM-TMP
11	only	only	RB	_	12	advmod	_
12	28	0	CD	_	13	num	_
13	days	day	NNS	_	10	pobj	_
14	,	,	,	_	16	punct	_
15	they	they	PRP	_	16	nsubj	16:A0=PAG
16	noted	note	VBD	pb=note.01	0	root	_
17	.	.	.	_	16	punct	_

1	In	in	IN	_	17	prep	17:AM-DIS
2	addition	addition	NN	_	1	pobj	_
3	,	,	,	_	17	punct	_
4	after	after	IN	p2=RB	17	prep	17:AM-TMP
5	4	0	CD	_	6	num	_
6	months	month	NNS	_	4	pobj	_
7	of	of	IN	_	6	prep	_
8	treatment	treatment	NN	_	7	pobj	_
9	,	,	,	_	17	punct	_
10	89.4	0	CD	_	11	num	_
11	%	%	NN	_	17	nsubj	17:A0=PAG
12	of	of	IN	_	11	prep	_
13	patients	patient	NNS	_	12	pobj	14:A0=PAG
14	receiving	receive	VBG	pb=receive.01	13	partmod	_
15	tocilizumab	tocilizumab	NN	p2=NNP	14	dobj	14:A1=PPT
16	had	have	VBD	_	17	aux	_
17	achieved	achieve	VBN	pb=achieve.01	50	ccomp	_
18	a	a	DT	_	21	det	_
19	30	0	CD	_	20	num	_
20	%	%	NN	_	21	nn	_
21	response	response	NN	_	17	dobj	17:A1=PPT
22	according	accord	VBG	_	17	prep	17:AM-ADV
23	to	to	IN	_	22	prep	_
24	the	the	DT	_	26	det	_
25	American	american	NNP	p2=JJ	26	nn	_
26	College	college	NNP	_	23	pobj	_
27	of	of	IN	_	26	prep	_
28	Rheumatology	rheumatology	NNP	_	29	nn	_
29	criteria	criterion	NNS	p2=NNP	27	pobj	_
30	(	(	-LRB-	_	26	punct	_
31	ACR30	acr30	NNP	p2=RB	26	appos	_
32	)	)	-RRB-	_	26	punct	_
33	,	,	,	_	17	punct	_
34	while	while	IN	_	40	mark	_
35	62.2	0	CD	_	36	num	_
36	%	%	NN	_	40	nsubj	40:A0=PAG
37	and	and	CC	_	36	cc	_
38	26.1	0	CD	_	39	num	_
39	%	%	NN	_	36	conj	_
40	had	have	VBD	pb=have.03	17	advcl	_
41	ACR70	acr70	NNP	p2=VBN	44	nn	_
42	and	and	CC	_	41	cc	_
43	ACR90	acr90	NNP	p2=NN	41	conj	_
44	responses	response	NNS	_	40	dobj	40:A1=PPT
45	,	,	,	_	40	punct	_
46	respectively	respectively	RB	_	40	advmod	40:AM-ADV
47	,	,	,	_	50	punct	_
48	the	the	DT	_	49	det	_
49	researchers	researcher	NNS	_	50	nsubj	50:A0=PAG
50	reported	report	VBD	pb=report.01	0	root	_
51	online	online	RB	p2=JJ	50	advmod	50:AM-LOC
52	in	in	IN	_	50	prep	50:AM-LOC
53	Annals	annal	NNPS	p2=NNS	52	pobj	_
54	of	of	IN	_	53	prep	_
55	the	the	DT	_	57	det	_
56	Rheumatic	rheumatic	NNP	p2=JJ	57	nn	_
57	Diseases	diseases	NNP	p2=NNPS	54	pobj	_
58	.	.	.	_	50	punct	_

1	JIA	jia	NNP	p2=NN	3	nsubjpass	3:A1=PPT;17:A1=PPT
2	is	be	VBZ	_	3	auxpass	_
3	classified	classify	VBN	p2=JJ|pb=classify.01	0	root	_
4	as	as	IN	_	5	advmod	_
5	polyarticular	polyarticular	JJ	p2=NNS	3	advcl	_
6	if	if	IN	_	12	mark	_
7	more	more	JJR	_	9	amod	_
8	than	than	IN	_	9	quantmod	_
9	four	#crd#	CD	_	10	num	_
10	joints	joint	NNS	_	12	nsubjpass	12:A1=PPT
11	are	be	VBP	_	12	auxpass	_
12	affected	affect	VBN	pb=affect.01	5	advcl	_
13	,	,	,	_	3	punct	_
14	and	and	CC	_	3	cc	_
15	can	can	MD	_	17	aux	17:AM-MOD
16	be	be	VB	_	17	auxpass	_
17	associated	associate	VBN	pb=associate.01	3	conj	_
18	with	with	IN	_	17	prep	17:A2=PPT
19	severe	severe	JJ	_	20	amod	_
20	disability	disability	NN	_	18	pobj	_
21	.	.	.	_	3	punct	_

1	It	it	PRP	_	2	nsubj	2:A1=PPT
2	differs	differ	VBZ	pb=differ.02	0	root	_
3	from	from	IN	_	2	prep	2:C-A1
4	systemic	systemic	JJ	p2=NN	6	hmod	_
5	-	-	HYPH	_	6	hyph	_
6	onset	onset	NN	_	7	nn	_
7	JIA	jia	NNP	p2=NN	3	pobj	_
8	in	in	IN	_	11	mark	_
9	that	that	IN	_	11	mark	_
10	it	it	PRP	_	11	nsubj	11:A0=PAG
11	lacks	lack	VBZ	pb=lack.01	2	advcl	_
12	rash	rash	NN	p2=JJ	11	dobj	11:A1=PPT
13	and	and	CC	_	12	cc	_
14	intermittent	intermittent	JJ	_	15	amod	_
15	fever	fever	NN	_	12	conj	_
16	along	along	IN	_	15	prep	_
17	with	with	IN	_	16	prep	_
18	the	the	DT	_	20	det	_
19	joint	joint	JJ	_	20	amod	_
20	involvement	involvement	NN	_	17	pobj	_
21	.	.	.	_	2	punct	_

1	A	a	DT	_	3	det	_
2	previous	previous	JJ	_	3	amod	_
3	study	study	NN	_	4	nsubj	4:A0;24:A0=CAU
4	demonstrated	demonstrate	VBD	pb=demonstrate.01	0	root	_
5	that	that	IN	_	15	complm	_
6	this	this	DT	_	9	det	_
7	interleukin	interleukin	NN	_	9	nn	_
8	(	(	-LRB-	_	9	punct	_
9	IL	il	NN	p2=NNP	14	nn	_
10	)	)	-RRB-	_	14	punct	_
11	-	-	HYPH	p2=:	12	hyph	_
12	6	0	CD	_	14	num	_
13	receptor	receptor	NN	p2=JJ	14	nn	_
14	antibody	antibody	NN	_	15	nsubj	15:A1=PPT
15	was	be	VBD	pb=be.01	4	ccomp	4:A1=PPT
16	effective	effective	JJ	_	15	acomp	15:A2=PRD
17	in	in	IN	_	16	prep	_
18	systemic	systemic	JJ	p2=NN	19	amod	_
19	JIA	jia	NNP	p2=NN	17	pobj	_
20	,	,	,	_	4	punct	_
21	and	and	CC	_	4	cc	_
22	has	have	VBZ	_	24	aux	_
23	also	also	RB	_	24	advmod	24:AM-DIS
24	shown	show	VBN	pb=show.01	4	conj	_
25	benefits	benefit	NNS	_	24	dobj	24:A1=PPT
26	for	for	IN	_	25	prep	_
27	adults	adult	NNS	_	26	pobj	_
28	with	with	IN	_	27	prep	_
29	rheumatoid	rheumatoid	JJ	p2=NN	30	amod	_
30	arthritis	arthritis	NN	_	28	pobj	_
31	.	.	.	_	4	punct	_

1	Because	because	IN	_	13	prep	13:AM-CAU
2	of	of	IN	_	1	pcomp	_
3	that	that	DT	_	5	det	_
4	previous	previous	JJ	_	5	amod	_
5	experience	experience	NN	_	1	pobj	_
6	and	and	CC	_	5	cc	_
7	because	because	IN	_	13	mark	_
8	IL	il	NN	p2=NNP	10	hmod	_
9	-	-	HYPH	_	10	hyph	_
10	6	0	CD	p2=NN	13	nsubjpass	13:A1=PAG
11	has	have	VBZ	_	13	aux	_
12	been	be	VBN	_	13	auxpass	_
13	detected	detect	VBN	pb=detect.01	0	root	_
14	at	at	IN	_	13	prep	13:AM-LOC
15	elevated	elevated	JJ	p2=VBN	16	amod	_
16	levels	level	NNS	_	14	pobj	_
17	in	in	IN	_	16	prep	_
18	the	the	DT	_	19	det	_
19	joints	joint	NNS	_	17	pobj	_
20	and	and	CC	_	19	cc	_
21	serum	serum	NN	p2=NNS	19	conj	_
22	of	of	IN	_	21	prep	_
23	children	child	NNS	_	22	pobj	_
24	with	with	IN	_	23	prep	_
25	polyarticular	polyarticular	JJ	p2=NN	26	nn	_
26	JIA	jia	NNP	_	24	pobj	_
27	and	and	CC	_	13	cc	_
28	appears	appear	VBZ	pb=appear.02	13	conj	_
29	to	to	TO	p2=IN	30	aux	_
30	correlate	correlate	VB	pb=correlate.01	28	xcomp	28:C-A1
31	with	with	IN	_	30	prep	30:A1=PPT
32	disease	disease	NN	p2=JJ	33	nn	_
33	severity	severity	NN	_	31	pobj	_
34	,	,	,	_	38	punct	_
35	Brunner	brunner	NNP	p2=NN	38	nsubj	38:A0
36	and	and	CC	_	35	cc	_
37	colleagues	colleague	NNS	_	35	conj	_
38	enrolled	enrol	VBD	pb=enroll.01	0	root	_
39	188	0	CD	_	40	num	_
40	patients	patient	NNS	_	38	dobj	38:A1
41	from	from	IN	_	38	prep	38:A2
42	58	0	CD	_	43	num	_
43	centers	center	NNS	_	41	pobj	_
44	throughout	throughout	IN	_	43	prep	_
45	the	the	DT	_	46	det	_
46	world	world	NN	_	44	pobj	_
47	in	in	IN	_	38	prep	38:AM-LOC
48	a	a	DT	_	52	det	_
49	three	#crd#	CD	_	51	hmod	_
50	-	-	HYPH	_	51	hyph	_
51	part	part	NN	_	52	nn	_
52	trial	trial	NN	_	47	pobj	_
53	of	of	IN	_	52	prep	_
54	tocilizumab	tocilizumab	NN	p2=RB	53	pobj	55:A1=PPT
55	known	know	VBN	pb=know.01	54	partmod	_
56	as	as	IN	_	55	prep	55:A2=PRD
57	CHERISH	cherish	NNP	_	56	pobj	_
58	.	.	.	_	38	punct	_

1	All	all	DT	_	2	det	_
2	participants	participant	NNS	_	5	nsubj	5:A0=PAG
3	had	have	VBD	_	5	aux	_
4	previously	previously	RB	_	5	advmod	5:AM-TMP
5	had	have	VBN	pb=have.03	0	root	_
6	an	an	DT	_	8	det	_
7	inadequate	inadequate	JJ	_	8	amod	_
8	response	response	NN	_	5	dobj	5:A1=PPT
9	to	to	IN	p2=TO	8	prep	_
10	methotrexate	methotrexate	NN	p2=PRP	9	pobj	_
11	,	,	,	_	5	punct	_
12	and	and	CC	_	5	cc	_
13	some	some	DT	_	16	nsubj	16:A1=PAG
14	had	have	VBD	_	16	aux	_
15	also	also	RB	_	16	advmod	16:AM-ADV
16	failed	fail	VBN	pb=fail.01	5	conj	_
17	on	on	IN	p2=RP	16	prep	16:A2=PPT
18	another	another	DT	_	20	det	_
19	biologic	biologic	JJ	_	20	amod	_
20	agent	agent	NN	_	17	pobj	_
21	.	.	.	_	16	punct	_

1	In	in	IN	_	23	prep	23:AM-LOC
2	the	the	DT	_	7	det	_
3	first	#ord#	JJ	_	7	amod	_
4	open	open	JJ	_	6	hmod	_
5	-	-	HYPH	_	6	hyph	_
6	label	label	NN	_	7	nn	_
7	phase	phase	NN	_	1	pobj	_
8	of	of	IN	_	7	prep	_
9	the	the	DT	_	10	det	_
10	study	study	NN	_	8	pobj	_
11	,	,	,	_	23	punct	_
12	children	child	NNS	_	23	nsubj	14:A0=PAG;23:A0=PAG
13	who	who	WP	_	14	nsubj	14:R-A0
14	weighed	weigh	VBD	pb=weigh.01	12	rcmod	_
15	30	0	CD	_	16	num	_
16	kg	kg	NNS	_	14	dobj	14:A1=PPT
17	(	(	-LRB-	_	16	punct	_
18	66	0	CD	_	19	num	_
19	lbs	lb	NNS	p2=NN	16	appos	_
20	)	)	-RRB-	_	16	punct	_
21	or	or	CC	_	16	cc	_
22	more	more	JJR	p2=RBR	23	advmod	_
23	received	receive	VBD	p2=VBN|pb=receive.01	0	root	_
24	8	0	CD	_	25	num	_
25	mg	mg	NN	p2=NNS	23	dobj	23:A1=PPT
26	/	/	SYM	p2=,	27	punct	_
27	kg	kg	NNS	p2=NN	25	appos	_
28	of	of	IN	_	27	prep	_
29	tocilizumab	tocilizumab	NN	p2=JJ	28	pobj	_
30	intravenously	intravenously	RB	_	31	advmod	_
31	once	once	RB	_	32	advmod	_
32	monthly	monthly	JJ	p2=RB	35	amod	_
33	for	for	IN	_	12	prep	_
34	4	0	CD	_	35	num	_
35	months	month	NNS	_	33	pobj	_
36	.	.	.	_	23	punct	_

1	Those	those	DT	_	9	nsubjpass	3:A0=PAG;12:A0=PAG;9:A1=PPT
2	who	who	WP	_	3	nsubj	3:R-A0
3	weighed	weigh	VBD	pb=weigh.01	1	rcmod	_
4	less	less	JJR	_	6	amod	_
5	than	than	IN	_	6	quantmod	_
6	30	0	CD	_	7	num	_
7	kg	kg	NNS	_	3	dobj	3:A1=PPT
8	were	be	VBD	_	9	auxpass	_
9	assigned	assign	VBN	pb=assign.01	0	root	_
10	randomly	randomly	RB	_	9	advmod	9:AM-MNR
11	to	to	TO	_	12	aux	_
12	receive	receive	VB	pb=receive.01	9	xcomp	9:A2=GOL
13	monthly	monthly	JJ	_	14	amod	_
14	doses	dose	NNS	_	12	dobj	12:A1=PPT
15	of	of	IN	_	14	prep	_
16	either	either	DT	p2=CC	20	preconj	_
17	8	0	CD	_	18	num	_
18	mg	mg	NN	p2=NNS	20	nn	_
19	/	/	SYM	p2=,	20	punct	_
20	kg	kg	NNS	p2=NN	15	pobj	_
21	or	or	CC	_	20	cc	_
22	10	0	CD	_	23	num	_
23	mg	mg	NNS	p2=NN	20	conj	_
24	/	/	SYM	p2=,	23	punct	_
25	kg	kg	NNS	p2=NN	23	appos	_
26	.	.	.	_	9	punct	_

1	Those	those	DT	_	0	root	3:A0=PAG;17:AM-LOC
2	who	who	WP	_	3	nsubj	3:R-A0
3	had	have	VBD	pb=have.03	1	rcmod	_
4	an	an	DT	_	5	det	_
5	ACR30	acr0	NN	p2=NNP	3	dobj	3:A1=PPT
6	or	or	CC	_	3	cc	_
7	better	good	JJR	_	8	amod	_
8	response	response	NN	_	9	nsubj	9:A0=PPT
9	entered	enter	VBD	p2=VBN|pb=enter.01	3	conj	_
10	part	part	NN	_	9	dobj	9:A1=LOC
11	two	#crd#	CD	_	10	num	_
12	,	,	,	_	9	punct	_
13	in	in	IN	_	17	prep	17:R-AM-LOC
14	which	which	WDT	_	13	pobj	_
15	they	they	PRP	_	17	nsubjpass	19:A0=PAG;24:A0=PAG;17:A1=PPT
16	were	be	VBD	_	17	auxpass	_
17	randomized	randomize	VBN	p2=JJ|pb=randomize.01	9	conj	_
18	to	to	TO	_	19	aux	_
19	continue	continue	VB	pb=continue.01	17	advcl	17:AM-PRP
20	tocilizumab	tocilizumab	NN	p2=NNS	19	dobj	19:A1=PPT
21	or	or	CC	_	20	cc	_
22	placebo	placebo	NN	_	20	conj	_
23	,	,	,	_	17	punct	_
24	continuing	continue	VBG	pb=continue.01	17	advcl	_
25	on	on	IN	_	24	prep	24:A1=PPT
26	background	background	NN	_	27	nn	_
27	methotrexate	methotrexate	NN	p2=NNS	25	pobj	_
28	and	and	CC	_	27	cc	_
29	steroids	steroid	NNS	_	27	conj	_
30	as	as	IN	_	31	mark	_
31	needed	need	VBN	pb=need.01	24	advcl	24:AM-TMP
32	.	.	.	_	17	punct	_

1	Part	part	NN	p2=NNP	7	nsubj	7:A1=PPT;13:A1=PPT
2	three	#crd#	CD	_	1	num	_
3	of	of	IN	_	1	prep	_
4	the	the	DT	_	5	det	_
5	study	study	NN	_	3	pobj	_
6	will	will	MD	_	7	aux	7:AM-MOD
7	extend	extend	VB	pb=extend.01	0	root	_
8	to	to	IN	_	7	prep	7:A2=EXT
9	64	0	CD	_	10	num	_
10	weeks	week	NNS	_	8	pobj	_
11	and	and	CC	_	7	cc	_
12	will	will	MD	_	13	aux	13:AM-MOD
13	consist	consist	VB	pb=consist.01	7	conj	_
14	of	of	IN	p2=RB	13	prep	13:A2=VSP
15	open	open	JJ	_	17	hmod	_
16	-	-	HYPH	_	17	hyph	_
17	label	label	NN	_	18	nn	_
18	tocilizumab	tocilizumab	NN	p2=NNS	14	pobj	_
19	in	in	IN	_	18	prep	_
20	the	the	DT	_	21	det	_
21	doses	dose	NNS	_	19	pobj	22:A1=PPT
22	given	give	VBN	pb=give.01	21	partmod	_
23	in	in	IN	_	22	prep	22:AM-LOC
24	part	part	NN	_	23	pobj	_
25	one	#crd#	CD	p2=NN	24	num	_
26	.	.	.	_	7	punct	_

1	Patients	patient	NNS	_	4	poss	_
2	'	'	POS	p2=''	1	possessive	_
3	mean	mean	JJ	p2=NN	4	amod	_
4	age	age	NN	_	5	nsubj	5:A1=PPT
5	was	be	VBD	pb=be.01	0	root	_
6	11	0	CD	_	7	num	_
7	years	year	NNS	_	5	npadvmod	5:A2=PRD
8	,	,	,	_	5	punct	_
9	and	and	CC	_	5	cc	_
10	three	#crd#	CD	_	12	hmod	_
11	-	-	HYPH	_	12	hyph	_
12	quarters	quarter	NNS	_	13	nsubj	13:A1=PPT
13	were	be	VBD	pb=be.01	5	conj	_
14	female	female	JJ	_	13	acomp	13:A2=PRD
15	.	.	.	_	13	punct	_

1	Disease	disease	JJ	p2=NNP	2	amod	_
2	duration	duration	NN	_	3	nsubj	3:A1=PPT
3	was	be	VBD	pb=be.01	0	root	_
4	slightly	slightly	RB	_	6	advmod	_
5	over	over	IN	_	6	quantmod	_
6	4	0	CD	_	7	num	_
7	years	year	NNS	_	3	attr	3:A2=PRD
8	,	,	,	_	3	punct	_
9	and	and	CC	_	3	cc	_
10	the	the	DT	_	12	det	_
11	mean	mean	JJ	_	12	amod	_
12	number	number	NN	_	18	nsubj	18:A1=PPT
13	of	of	IN	_	12	prep	_
14	joints	joint	NNS	_	13	pobj	_
15	with	with	IN	_	14	prep	_
16	active	active	JJ	_	17	amod	_
17	arthritis	arthritis	NN	_	15	pobj	_
18	was	be	VBD	pb=be.01	3	conj	_
19	20	0	CD	_	18	attr	18:A2=PRD
20	.	.	.	_	18	punct	_

1	In	in	IN	_	22	prep	22:AM-ADV
2	part	part	NN	_	1	pobj	_
3	one	#crd#	CD	_	2	num	_
4	of	of	IN	_	2	prep	_
5	the	the	DT	_	6	det	_
6	study	study	NN	_	4	pobj	_
7	,	,	,	_	22	punct	_
8	children	child	NNS	_	22	nsubj	9:A0=PAG;22:A0=PAG
9	weighing	weigh	VBG	pb=weigh.01	8	partmod	_
10	less	less	JJR	_	12	amod	_
11	than	than	IN	_	12	quantmod	_
12	30	0	CD	_	13	num	_
13	kg	kg	NNS	_	9	dobj	15:A0=PAG;9:A1=PPT
14	who	who	WP	_	15	nsubj	15:R-A0
15	received	receive	VBD	pb=receive.01	13	rcmod	_
16	the	the	DT	_	21	det	_
17	8	0	CD	_	20	num	_
18	mg	mg	NN	p2=NNS	20	nn	_
19	/	/	SYM	p2=WDT	20	punct	_
20	kg	kg	NNS	p2=NN	21	nn	_
21	dose	dose	NN	p2=VBP	15	dobj	15:A1=PPT
22	had	have	VBD	pb=have.03	0	root	_
23	lower	low	JJR	p2=RBR	25	amod	_
24	ACR30/70/90	acr0	NN	p2=NNP	25	nn	_
25	responses	response	NNS	_	22	dobj	22:A1=PPT
26	than	than	IN	_	25	prep	_
27	the	the	DT	_	29	det	_
28	other	other	JJ	_	29	amod	_
29	groups	group	NNS	_	26	pobj	_
30	.	.	.	_	22	punct	_

1	In	in	IN	_	9	prep	9:AM-LOC;18:AM-LOC
2	the	the	DT	_	4	det	_
3	second	#ord#	JJ	_	4	amod	_
4	part	part	NN	_	1	pobj	_
5	,	,	,	_	9	punct	_
6	rates	rate	NNS	_	9	nsubj	9:A1=PPT;18:A1=PPT
7	of	of	IN	_	6	prep	_
8	ACR70/90	acr70/90	NNP	p2=NNS	7	pobj	_
9	were	be	VBD	pb=be.01	0	root	_
10	higher	high	JJR	_	9	acomp	9:A2=PRD
11	in	in	IN	_	9	prep	9:AM-LOC
12	patients	patient	NNS	_	11	pobj	14:A0=PAG
13	also	also	RB	_	14	advmod	14:AM-DIS
14	receiving	receive	VBG	pb=receive.01	12	partmod	_
15	methotrexate	methotrexate	NN	p2=NNS	14	dobj	14:A1=PPT
16	,	,	,	_	9	punct	_
17	but	but	CC	_	9	cc	_
18	were	be	VBD	pb=be.01	9	conj	_
19	lower	low	JJR	p2=RBR	18	acomp	18:A2=PRD
20	in	in	IN	_	18	prep	18:AM-LOC
21	those	those	DT	_	20	pobj	25:A0=PAG
22	who	who	WP	_	25	nsubj	25:R-A0
23	had	have	VBD	_	25	aux	_
24	previously	previously	RB	_	25	advmod	25:AM-TMP
25	received	receive	VBN	pb=receive.01	21	rcmod	_
26	biologics	biologics	NNS	_	25	dobj	25:A1=PPT
27	.	.	.	_	9	punct	_

1	Other	other	JJ	_	2	amod	_
2	studies	study	NNS	_	19	nsubj	19:A0=PAG
3	of	of	IN	_	2	prep	_
4	biologics	biologics	NNS	p2=NN	3	pobj	_
5	in	in	IN	_	4	prep	_
6	children	child	NNS	_	5	pobj	12:A0=PAG
7	with	with	IN	_	6	prep	_
8	JIA	jia	NNP	_	7	pobj	_
9	who	who	WP	_	12	nsubj	12:R-A0
10	have	have	VBP	_	12	aux	_
11	not	not	RB	_	12	neg	12:AM-NEG
12	responded	respond	VBN	p2=VBD|pb=respond.01	6	rcmod	_
13	to	to	IN	p2=TO	12	prep	12:A1=GOL
14	previous	previous	JJ	_	16	amod	_
15	biologic	biologic	NN	p2=JJ	16	nn	_
16	therapy	therapy	NN	_	13	pobj	_
17	have	have	VBP	_	19	aux	_
18	also	also	RB	_	19	advmod	19:AM-DIS
19	found	find	VBN	pb=find.01	36	ccomp	_
20	lower	low	JJR	_	22	amod	_
21	response	response	NN	_	22	nn	_
22	rates	rate	NNS	_	19	dobj	19:A1=PPT
23	,	,	,	_	19	punct	_
24	and	and	CC	_	19	cc	_
25	these	these	DT	_	26	det	_
26	children	child	NNS	_	28	nsubj	28:A0=PAG
27	may	may	MD	_	28	aux	28:AM-MOD
28	represent	represent	VB	pb=represent.01	19	conj	_
29	a	a	DT	_	32	det	_
30	particularly	particularly	RB	_	31	advmod	_
31	refractory	refractory	JJ	_	32	amod	_
32	population	population	NN	_	28	dobj	28:A1=PPT
33	,	,	,	_	36	punct	_
34	the	the	DT	_	35	det	_
35	researchers	researcher	NNS	_	36	nsubj	36:A0=PAG
36	observed	observe	VBD	pb=observe.02	0	root	_
37	.	.	.	_	36	punct	_

1	During	during	IN	_	9	prep	9:AM-TMP
2	the	the	DT	_	3	det	_
3	study	study	NN	_	1	pobj	_
4	,	,	,	_	9	punct	_
5	9	0	CD	_	6	num	_
6	%	%	NN	_	9	nsubj	9:A0=PPT
7	of	of	IN	_	6	prep	_
8	patients	patient	NNS	_	7	pobj	_
9	experienced	experience	VBD	pb=experience.01	0	root	_
10	22	0	CD	_	13	num	_
11	serious	serious	JJ	_	13	amod	_
12	adverse	adverse	JJ	_	13	amod	_
13	events	event	NNS	_	9	dobj	9:A1=PAG
14	.	.	.	_	9	punct	_

1	Five	#crd#	CD	_	13	nsubjpass	13:A1=PPT;15:A1=PPT
2	of	of	IN	_	1	prep	_
3	these	these	DT	_	4	det	_
4	events	event	NNS	_	2	pobj	_
5	,	,	,	_	1	punct	_
6	such	such	JJ	_	7	amod	_
7	as	as	IN	_	1	prep	_
8	pneumonia	pneumonia	NN	_	7	pobj	_
9	and	and	CC	_	8	cc	_
10	cellulitis	cellulitis	NN	p2=NNS	8	conj	_
11	,	,	,	_	13	punct	_
12	were	be	VBD	_	13	auxpass	_
13	thought	think	VBN	pb=think.01	0	root	_
14	to	to	TO	_	15	aux	_
15	be	be	VB	pb=be.01	13	xcomp	13:C-A1
16	treatment	treatment	NN	_	18	hmod	_
17	-	-	HYPH	_	18	hyph	_
18	related	relate	VBN	p2=JJ	15	acomp	15:A2=PRD
19	.	.	.	_	13	punct	_

1	Among	among	IN	_	4	prep	4:A2=PRD
2	laboratory	laboratory	NN	_	3	nn	_
3	abnormalities	abnormality	NNS	_	1	pobj	_
4	were	be	VBD	pb=be.01	0	root	_
5	increases	increase	NNS	_	4	nsubj	4:A1=PPT
6	in	in	IN	_	5	prep	_
7	liver	liver	NN	_	8	nn	_
8	enzymes	enzyme	NNS	p2=VBZ	6	pobj	_
9	,	,	,	_	8	punct	_
10	neutropenia	neutropenia	NN	p2=NNS	8	conj	_
11	,	,	,	_	10	punct	_
12	and	and	CC	_	10	cc	_
13	thrombocytopenia	thrombocytopenia	NN	p2=JJ	10	conj	_
14	,	,	,	_	4	punct	_
15	but	but	CC	_	4	cc	_
16	no	no	DT	_	17	det	_
17	relation	relation	NN	_	19	nsubjpass	19:A1
18	was	be	VBD	_	19	auxpass	_
19	seen	see	VBN	pb=see.01	4	conj	_
20	with	with	IN	_	19	prep	19:AM-MNR
21	infections	infection	NNS	_	20	pobj	_
22	or	or	CC	_	21	cc	_
23	bleeding	bleed	VBG	p2=NN|pb=bleed.01	21	conj	_
24	.	.	.	_	19	punct	_

1	As	as	IN	p2=NNP	4	mark	_
2	has	have	VBZ	_	4	aux	_
3	been	be	VBN	_	4	auxpass	_
4	seen	see	VBN	pb=see.01	11	advcl	11:AM-ADV
5	in	in	IN	_	4	prep	4:AM-LOC
6	adults	adult	NNS	_	5	pobj	_
7	,	,	,	_	11	punct	_
8	increases	increase	NNS	_	11	nsubjpass	11:A1
9	also	also	RB	_	11	advmod	11:AM-ADV
10	were	be	VBD	_	11	auxpass	_
11	seen	see	VBN	pb=see.01	0	root	_
12	in	in	IN	_	11	prep	11:AM-LOC
13	total	total	JJ	p2=NN	17	amod	_
14	and	and	CC	_	13	cc	_
15	LDL	ldl	NNP	p2=JJ	17	nn	_
16	cholesterol	cholesterol	NN	_	17	nn	_
17	levels	level	NNS	_	12	pobj	_
18	.	.	.	_	11	punct	_

1	"	"	``	p2=''	51	punct	_
2	Tocilizumab	tocilizumab	NNP	p2=JJ	3	nn	_
3	treatment	treatment	NN	_	4	nsubj	4:A0
4	provided	provided	VBN	p2=VBD|pb=provide.01	51	ccomp	51:A1=PPT
5	sustained	sustain	VBD	p2=JJ|pb=sustain.02	9	amod	_
6	and	and	CC	_	5	cc	_
7	clinically	clinically	RB	p2=VB	8	advmod	_
8	meaningful	meaningful	JJ	_	9	amod	_
9	improvement	improvement	NN	_	4	dobj	4:A1;5:A1=PPT
10	for	for	IN	_	9	prep	_
11	patients	patient	NNS	_	10	pobj	_
12	with	with	IN	_	11	prep	_
13	[	[	-LRB-	p2=``	16	punct	_
14	polyarticular	polyarticular	JJ	p2=NN	16	hmod	_
15	-	-	HYPH	_	16	hyph	_
16	course	course	NN	_	12	pobj	_
17	]	]	-RRB-	_	16	punct	_
18	JIA	jia	NNP	_	16	appos	_
19	on	on	IN	p2=RP	18	prep	_
20	monthly	monthly	JJ	p2=RB	21	amod	_
21	dosing	dosing	NN	p2=NNS	19	pobj	_
22	of	of	IN	_	21	prep	_
23	8	0	CD	_	24	num	_
24	mg	mg	NNS	p2=NN	22	pobj	_
25	/	/	SYM	p2=,	26	punct	_
26	kg	kg	NNS	p2=NN	24	appos	_
27	in	in	IN	_	24	prep	_
28	patients	patient	NNS	_	27	pobj	_
29	weighing	weigh	VBG	pb=weigh.01	28	partmod	_
30	30	0	CD	_	31	num	_
31	kg	kg	NNS	_	29	dobj	29:A3=VSP
32	or	or	CC	_	31	cc	_
33	more	more	JJR	p2=RBR	31	conj	_
34	and	and	CC	_	33	cc	_
35	10	0	CD	_	33	conj	_
36	mg	mg	NNS	p2=NN	38	nn	_
37	/	/	SYM	p2=,	38	punct	_
38	kg	kg	NNS	p2=NN	28	appos	_
39	in	in	IN	_	28	prep	_
40	patients	patient	NNS	_	39	pobj	41:A0=PAG
41	weighing	weigh	VBG	pb=weigh.01	40	partmod	_
42	less	less	JJR	_	44	amod	_
43	than	than	IN	_	44	quantmod	_
44	30	0	CD	_	45	num	_
45	kg	kg	NNS	p2=NN	41	dobj	41:A1=PPT
46	,	,	,	_	51	punct	_
47	"	"	''	p2=``	51	punct	_
48	Brunner	brunner	NNP	p2=JJR	51	nsubj	51:A0=PAG
49	and	and	CC	_	48	cc	_
50	colleagues	colleague	NNS	_	48	conj	_
51	concluded	conclude	VBD	pb=conclude.01	0	root	_
52	.	.	.	_	51	punct	_

1	A	a	DT	_	2	det	_
2	limitation	limitation	NN	_	6	nsubj	6:A1=PPT
3	of	of	IN	_	2	prep	_
4	the	the	DT	_	5	det	_
5	study	study	NN	_	3	pobj	_
6	was	be	VBD	pb=be.01	0	root	_
7	the	the	DT	_	8	det	_
8	withdrawal	withdrawal	NN	_	6	attr	14:A0=PAG;6:A2=PRD
9	of	of	IN	_	8	prep	_
10	patients	patient	NNS	_	9	pobj	_
11	who	who	WP	_	14	nsubj	14:R-A0
12	did	do	VBD	_	14	aux	_
13	n't	not	RB	_	14	neg	14:AM-NEG
14	have	have	VB	pb=have.03	8	rcmod	_
15	an	an	DT	_	17	det	_
16	ACR30	acr30	NNP	p2=VBN	17	nn	_
17	response	response	NN	_	14	dobj	14:A1=PPT
18	in	in	IN	_	14	prep	14:AM-ADV
19	part	part	NN	_	18	pobj	_
20	one	#crd#	CD	_	19	num	_
21	of	of	IN	_	19	prep	_
22	the	the	DT	_	23	det	_
23	trial	trial	NN	_	21	pobj	_
24	.	.	.	_	6	punct	_

1	The	the	DT	_	2	det	_
2	study	study	NN	_	4	nsubjpass	4:A1=PPT
3	was	be	VBD	_	4	auxpass	_
4	funded	fund	VBN	pb=fund.01	0	root	_
5	by	by	IN	_	4	agent	4:A0=PAG
6	Hoffmann	hoffmann	NNP	_	8	hmod	_
7	-	-	HYPH	_	8	hyph	_
8	La	la	NNP	_	10	nn	_
9	Roche	roche	NNP	_	10	nn	_
10	Ltd.	ltd.	NNP	_	5	pobj	_
11	The	the	DT	p2=NNP	12	det	_
12	investigators	investigator	NNS	_	13	nsubj	13:A0
13	disclosed	disclose	VBD	pb=disclose.01	4	advcl	4:AM-TMP
14	multiple	multiple	JJ	_	17	amod	_
15	relevant	relevant	JJ	_	17	amod	_
16	financial	financial	JJ	_	17	amod	_
17	relationships	relationship	NNS	_	13	dobj	13:A1=PPT
18	with	with	IN	_	17	prep	_
19	companies	company	NNS	_	18	pobj	_
20	including	include	VBG	_	19	prep	_
21	Roche	roche	NNP	_	20	pobj	_
22	,	,	,	_	21	punct	_
23	AbbVie	abbvie	NNP	_	21	conj	_
24	,	,	,	_	23	punct	_
25	Pfizer	pfizer	NNP	_	23	conj	_
26	,	,	,	_	25	punct	_
27	AstraZeneca	astrazeneca	NNP	_	25	conj	_
28	,	,	,	_	27	punct	_
29	GlaxoSmithKline	glaxosmithkline	NNP	_	27	conj	_
30	,	,	,	_	29	punct	_
31	Novartis	novartis	NNP	_	29	conj	_
32	,	,	,	_	31	punct	_
33	Bristol	bristol	NNP	_	35	hmod	_
34	-	-	HYPH	_	35	hyph	_
35	Myers	myers	NNP	_	36	nn	_
36	Squibb	squibb	NNP	_	31	conj	_
37	,	,	,	_	36	punct	_
38	Eli	eli	NNP	_	39	nn	_
39	Lilly	lilly	NNP	_	36	conj	_
40	,	,	,	_	39	punct	_
41	UCB	ucb	NNP	_	39	conj	_
42	,	,	,	_	41	punct	_
43	MedImmune	medimmune	NNP	_	41	conj	_
44	,	,	,	_	43	punct	_
45	and	and	CC	_	43	cc	_
46	Novo	novo	NNP	_	47	nn	_
47	Nordisk	nordisk	NNP	_	43	conj	_
48	.	.	.	_	4	punct	_

1	This	this	DT	_	2	det	_
2	survey	survey	NN	_	3	nsubj	3:A1=PPT
3	is	be	VBZ	pb=be.01	0	root	_
4	a	a	DT	_	5	det	_
5	poll	poll	NN	_	3	attr	3:A2=PRD
6	of	of	IN	_	5	prep	_
7	those	those	DT	_	6	pobj	9:A0=PAG;11:A0=PAG;13:A1=PPT
8	who	who	WP	_	9	nsubj	9:R-A0;11:R-A0;13:R-A1
9	choose	choose	VBP	pb=choose.01	7	rcmod	_
10	to	to	TO	_	11	aux	_
11	participate	participate	VB	pb=participate.01	9	xcomp	9:A1=PPT
12	and	and	CC	_	9	cc	_
13	are	be	VBP	p2=VB|pb=be.01	9	conj	_
14	,	,	,	_	13	punct	_
15	therefore	therefore	RB	_	20	advmod	_
16	,	,	,	_	20	punct	_
17	not	not	RB	_	18	neg	_
18	valid	valid	JJ	_	20	amod	_
19	statistical	statistical	JJ	_	20	amod	_
20	samples	sample	NNS	_	13	attr	13:A2=PRD
21	,	,	,	_	20	punct	_
22	but	but	CC	_	20	cc	_
23	rather	rather	RB	_	22	advmod	_
24	a	a	DT	_	25	det	_
25	snapshot	snapshot	NN	_	3	conj	_
26	of	of	IN	_	25	prep	_
27	what	what	WP	_	31	dobj	31:R-A1
28	your	your	PRP$	_	29	poss	_
29	colleagues	colleague	NNS	_	31	nsubj	31:A0
30	are	be	VBP	_	31	aux	_
31	thinking	think	VBG	p2=JJ|pb=think.01	26	pcomp	_
32	.	.	.	_	3	punct	_

1	MedPageToday	medpagetoday	NNP	p2=NN	0	root	3:A1=GOL
2	,	,	,	_	1	punct	_
3	powered	power	VBN	pb=power.01	1	partmod	_
4	by	by	IN	_	3	agent	3:A0=PAG
5	Everyday	everyday	NNP	_	7	nn	_
6	Health	health	NNP	_	7	nn	_
7	Inc	inc	NNP	_	4	pobj	_
8	.	.	.	_	1	punct	_

1	,	,	,	_	2	punct	_
2	is	be	VBZ	pb=be.01	0	root	_
3	a	a	DT	_	7	det	_
4	trusted	trusted	JJ	_	7	amod	_
5	and	and	CC	_	4	cc	_
6	reliable	reliable	JJ	_	4	conj	_
7	source	source	NN	_	2	attr	2:A2=PRD
8	for	for	IN	_	7	prep	_
9	clinical	clinical	JJ	_	12	amod	_
10	and	and	CC	_	9	cc	_
11	policy	policy	NN	_	9	conj	_
12	coverage	coverage	NN	_	8	pobj	15:A0=PAG
13	that	that	WDT	_	15	nsubj	15:R-A0
14	directly	directly	RB	_	15	advmod	15:AM-MNR
15	affects	affect	VBZ	pb=affect.01	12	rcmod	_
16	the	the	DT	_	17	det	_
17	lives	life	NNS	_	15	dobj	15:A1=PPT
18	and	and	CC	_	17	cc	_
19	practices	practice	NNS	_	17	conj	_
20	of	of	IN	_	19	prep	_
21	health	health	NN	_	22	nn	_
22	care	care	NN	_	23	nn	_
23	professionals	professional	NNS	_	20	pobj	_
24	.	.	.	_	2	punct	_

1	Physicians	physicians	NNP	p2=NNPS	8	nsubj	8:A0=PAG
2	and	and	CC	_	1	cc	_
3	other	other	JJ	_	5	amod	_
4	healthcare	healthcare	NN	_	5	nn	_
5	professionals	professional	NNS	_	1	conj	_
6	may	may	MD	_	8	aux	8:AM-MOD
7	also	also	RB	_	8	advmod	8:AM-DIS
8	receive	receive	VB	pb=receive.01	0	root	_
9	Continuing	continuing	NNP	_	11	nn	_
10	Medical	medical	NNP	_	11	nn	_
11	Education	education	NNP	_	8	dobj	8:A1=PPT
12	(	(	-LRB-	_	11	punct	_
13	CME	cme	NNP	_	11	appos	_
14	)	)	-RRB-	_	11	punct	_
15	and	and	CC	_	11	cc	_
16	Continuing	continuing	NNP	_	17	nn	_
17	Education	education	NNP	_	11	conj	_
18	(	(	-LRB-	_	19	punct	_
19	CE	ce	NNP	_	17	appos	_
20	)	)	-RRB-	_	19	punct	_
21	credits	credit	VBZ	p2=NNS	8	dobj	_
22	at	at	IN	_	8	prep	8:AM-MNR
23	no	no	DT	_	24	det	_
24	cost	cost	NN	_	22	pobj	_
25	for	for	IN	_	24	prep	_
26	participating	participate	VBG	pb=participate.01	25	pcomp	_
27	in	in	IN	p2=RP	26	prep	26:A1=PPT
28	MedPage	medpage	NNP	_	29	nn	_
29	Today	today	NNP	p2=NN	31	hmod	_
30	-	-	HYPH	p2=:	31	hyph	_
31	hosted	host	VBN	p2=VBD	33	amod	_
32	educational	educational	JJ	_	33	amod	_
33	activities	activity	NNS	_	27	pobj	_
34	.	.	.	_	8	punct	_

1	©	©	SYM	p2=IN	4	punct	_
2	2014	0	CD	_	4	num	_
3	MedPage	medpage	NNP	p2=NN	4	nn	_
4	Today	today	NN	p2=NNP	0	root	_
5	,	,	,	_	4	punct	_
6	LLC	llc	NNP	_	4	appos	_
7	.	.	.	_	3	punct	_

1	All	all	DT	_	2	det	_
2	rights	right	NNS	_	3	nsubj	3:A1=PPT
3	reserved	reserve	VBN	p2=VBD|pb=reserve.01	0	root	_
4	.	.	.	_	3	punct	_

1	Use	use	NN	p2=VB	5	nsubj	5:A0=PAG
2	of	of	IN	_	1	prep	_
3	this	this	DT	_	4	det	_
4	site	site	NN	_	2	pobj	_
5	constitutes	constitute	VBZ	pb=constitute.01	0	root	_
6	acceptance	acceptance	NN	_	5	dobj	5:A1=PPT
7	of	of	IN	_	6	prep	_
8	the	the	DT	_	10	det	_
9	MedPageToday.com	#url#	ADD	_	10	amod	_
10	terms	term	NNS	_	7	pobj	_
11	of	of	IN	_	10	prep	_
12	use	use	NN	_	11	pobj	_
13	and	and	CC	_	12	cc	_
14	privacy	privacy	NN	_	15	nn	_
15	policy	policy	NN	_	12	conj	_
16	.	.	.	_	5	punct	_

1	The	the	DT	_	2	det	_
2	material	material	NN	_	6	nsubj	6:A1=PPT;13:A1=PPT
3	on	on	IN	_	2	prep	_
4	this	this	DT	_	5	det	_
5	site	site	NN	_	3	pobj	_
6	is	be	VBZ	pb=be.01	0	root	_
7	for	for	IN	_	6	prep	6:A2=PRD
8	informational	informational	JJ	_	9	amod	_
9	purposes	purpose	NNS	_	7	pobj	_
10	only	only	RB	_	9	advmod	_
11	,	,	,	_	6	punct	_
12	and	and	CC	_	6	cc	_
13	is	be	VBZ	pb=be.01	6	conj	_
14	not	not	RB	_	13	neg	13:AM-NEG
15	a	a	DT	_	16	det	_
16	substitute	substitute	NN	_	13	attr	13:A2=PRD
17	for	for	IN	_	16	prep	_
18	medical	medical	JJ	_	19	amod	_
19	advice	advice	NN	_	17	pobj	24:A1
20	,	,	,	_	19	punct	_
21	diagnosis	diagnosis	NN	_	24	nsubj	_
22	or	or	CC	_	21	cc	_
23	treatment	treatment	NN	_	21	conj	_
24	provided	provided	VBN	pb=provide.01	19	partmod	_
25	by	by	IN	_	24	agent	24:A0
26	a	a	DT	_	30	det	_
27	qualified	qualified	JJ	_	30	amod	_
28	health	health	NN	_	29	nn	_
29	care	care	NN	_	30	nn	_
30	provider	provider	NN	_	25	pobj	_
31	.	.	.	_	6	punct	_

